

Agnes LABIGNE et al.
Serial No. 08/211,312

Attorney Docket No.: 2356.0074

IN THE CLAIMS:

Please cancel claims 18, 19, and 37-39 without prejudice or disclaimer and add the following new claims:

5b

40. A purified polypeptide having the amino acid sequence of at least one of the polypeptides selected from the group consisting of UreE, UreF, UreG, UreH, and UreI, as shown in Figure 4 (SEQ. ID NOS: 4-7 and 3, respectively), or a fragment thereof.

2
41. The purified polypeptide of claim *40*, wherein said polypeptide is UreE.

3
42. The purified polypeptide of claim *40*, wherein said polypeptide is UreF.

4
43. The purified polypeptide of claim *40*, wherein said polypeptide is UreG.

5
44. The purified polypeptide of claim *40*, wherein said polypeptide is UreH.

6
45. The purified polypeptide of claim *40*, wherein said polypeptide is UreI.

46. A purified polypeptide having an amino acid sequence expressed by a gene selected from the group consisting of ureE, ureF, ureG, ureH, and ureI (SEQ ID NO:1) of H. pylori, or a mutant thereof.

47. The purified polypeptide of claim 46, wherein said gene is ureE (SEQ ID NO:1) or a mutant thereof.

48. The purified polypeptide of claim 46, wherein said gene is ureF (SEQ ID NO:1) or a mutant thereof.

49. The purified polypeptide of claim 46, wherein said gene is ureG (SEQ ID NO:1) or a mutant thereof.

5b

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000

50. The purified polypeptide of claim 46, wherein said gene is ureH (SEQ ID NO:1) or a mutant thereof.

51. The purified polypeptide of claim 46, wherein said gene is ureI (SEQ ID NO:1) or a mutant thereof.

52. A purified polypeptide having the following amino acid sequence:

Ala Lys Ile Cys Tyr Glu Ile Gly Asn Arg His^(SEQ ID NO:9)

53. A purified antibody, which binds to the polypeptide according to any one of claims

1-6
40-45

54. A purified antibody, which binds to the polypeptide according to any one of claims

46-51.

55. A purified antibody, which binds to the polypeptide according to claim 52.

56. A composition comprising the antibody of claim 53 and a pharmaceutically acceptable carrier.

57. A composition comprising the antibody of claim 54 and a pharmaceutically acceptable carrier.

58. A composition comprising the antibody of claim 55 and a pharmaceutically acceptable carrier.

59. A composition comprising the polypeptide of any one of claims 40-45 and a pharmaceutically acceptable carrier.

60. A composition comprising the polypeptide of any one of claims 46-51 and a pharmaceutically acceptable carrier.